If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Rezvoglar ™ (insulin glargine-aglr) injection
3 mL (100 units/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the route of administration for Rezvoglar™ (insulin glargine-aglr)?
Rezvoglar is administered as a subcutaneous injection.
Route of Administration
Administer Rezvoglar™ (insulin glargine-aglr) 100 units/mL subcutaneously into the abdominal area, thigh, or deltoid.1
Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.1
Do not dilute or mix Rezvoglar with any other insulin or solution.1
Do not administer Rezvoglar intravenously or via an insulin pump.1
Route of Administration Versus Duration of Action
In patients with type 1 diabetes, after subcutaneous injection of another insulin glargine 100 units/mL product, the duration of action after abdominal, deltoid, or thigh administration was similar.1
Enclosed Prescribing Information
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: February 02, 2022